Michael Emig

5PUBLICATIONS
69CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Innate immunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Oct 08, 2026
Roginolisib in Combination with JAK Inhibitors in Patients with Myelofibrosis Who are Unresponsive to Approved JAK Inhibitors (Study HEMA-MED) - A Trial in Progress.

|Apr 04, 2025
Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial.

Yago Nieto, Pinaki Banerjee, Indreshpal Kaur

|Jan 23, 2025
First-in-Human Phase I Study of a CD16A Bispecific Innate Cell Engager, AFM24, Targeting EGFR-Expressing Solid Tumors.

Anthony El-Khoueiry, Omar Saavedra, Jacob Thomas

|Nov 12, 2024
A Phase II Study of Acimtamig (AFM13) in Patients with CD30-Positive, Relapsed, or Refractory Peripheral T-cell Lymphomas.

Won Seog Kim, Jake Shortt, Pier Luigi Zinzani

Pageof 1

Frequent Collaborators

3 joint publications

Andre Overesch

2 joint publications

Rafet Basar

2 joint publications

Amin Alousi

2 joint publications

Hind Rafei